ES2823127T3 - Compuestos tricíclicos de quinolina y azaquinolina sustituidos con heteroarilo como inhibidores de PAR4 - Google Patents

Compuestos tricíclicos de quinolina y azaquinolina sustituidos con heteroarilo como inhibidores de PAR4 Download PDF

Info

Publication number
ES2823127T3
ES2823127T3 ES17742926T ES17742926T ES2823127T3 ES 2823127 T3 ES2823127 T3 ES 2823127T3 ES 17742926 T ES17742926 T ES 17742926T ES 17742926 T ES17742926 T ES 17742926T ES 2823127 T3 ES2823127 T3 ES 2823127T3
Authority
ES
Spain
Prior art keywords
ethyl
thiazol
ethoxy
benzo
dioxino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17742926T
Other languages
English (en)
Spanish (es)
Inventor
Xiaojun Zhang
Eldon Scott Priestley
Oz Scott Halpern
Wen Jiang
Samuel Kaye Reznik
Jeremy M Richter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ES2823127T3 publication Critical patent/ES2823127T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ES17742926T 2016-07-14 2017-07-13 Compuestos tricíclicos de quinolina y azaquinolina sustituidos con heteroarilo como inhibidores de PAR4 Active ES2823127T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662362121P 2016-07-14 2016-07-14
PCT/US2017/041880 WO2018013776A1 (en) 2016-07-14 2017-07-13 Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as par4 inhibitors

Publications (1)

Publication Number Publication Date
ES2823127T3 true ES2823127T3 (es) 2021-05-06

Family

ID=59384259

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17742926T Active ES2823127T3 (es) 2016-07-14 2017-07-13 Compuestos tricíclicos de quinolina y azaquinolina sustituidos con heteroarilo como inhibidores de PAR4

Country Status (7)

Country Link
US (3) US20190315774A1 (enExample)
EP (1) EP3484894B1 (enExample)
JP (1) JP6903732B2 (enExample)
KR (1) KR102468661B1 (enExample)
CN (1) CN109689664B (enExample)
ES (1) ES2823127T3 (enExample)
WO (1) WO2018013776A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109689664B (zh) 2016-07-14 2022-04-15 百时美施贵宝公司 作为par4抑制剂的三环杂芳基取代的喹啉和氮杂喹啉化合物
WO2018013774A1 (en) 2016-07-14 2018-01-18 Bristol-Myers Squibb Company Bicyclic heteroaryl substituted compounds
EP3484874B1 (en) * 2016-07-14 2020-04-29 Bristol-Myers Squibb Company Monocyclic heteroaryl substituted compounds
CN109689649B (zh) 2016-07-14 2022-07-19 百时美施贵宝公司 经二环杂芳基取代的化合物
CN111440146B (zh) * 2020-05-15 2022-10-21 中国药科大学 一种具有par4拮抗活性的苯并三嗪类化合物及其应用
CN117285527A (zh) * 2023-09-25 2023-12-26 中国药科大学 一种噌啉类par4拮抗剂及其医药应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1164459A (en) * 1980-11-11 1984-03-27 Yung-Hsiung Yang Process for preparing (imidazo¬1,2-a|pyridine- 2-yl)-carbostyril or -3,4-dihydrocarbostyryl derivatives
TW279162B (enExample) * 1991-09-26 1996-06-21 Mitsubishi Chem Corp
JP2928079B2 (ja) 1994-02-14 1999-07-28 永信薬品工業股▲ふん▼有限公司 １−（置換ベンジル）−３−（置換アリール）縮合ピラゾール類、その製造法及びその用途
US6166041A (en) 1995-10-11 2000-12-26 Euro-Celtique, S.A. 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
US6387942B2 (en) * 2000-06-19 2002-05-14 Yung Shin Pharmaceutical Ind. Co. Ltd Method of treating disorders related to protease-activated receptors-induced cell activation
EP1348701A1 (en) 2002-03-28 2003-10-01 Warner-Lambert Company LLC (2,4-disubstituted-thiazol-5-yl) amine compounds as PDE7 inhibitors
CA2534649A1 (en) 2003-08-01 2005-02-10 Genelabs Technologies, Inc. Bicyclic imidazol derivatives against flaviviridae
US20050272784A1 (en) 2004-05-07 2005-12-08 Xiaobing Li Inhibitors of bacterial Type III protein secretion systems
CN101365696A (zh) 2004-07-28 2009-02-11 Irm责任有限公司 作为类固醇激素核受体调节剂的化合物和组合物
JP2008526980A (ja) 2005-01-14 2008-07-24 ジェネラブズ テクノロジーズ インコーポレーティッド ウイルス感染症を治療するためのインドール誘導体
WO2007149395A2 (en) 2006-06-20 2007-12-27 Amphora Discovery Corporation 2,5-substituted oxazole derivatives as protein kinase inhibitors for the treatment of cancer
RU2424233C2 (ru) 2006-06-29 2011-07-20 Ф.Хоффманн-Ля Рош Аг Производные бензимидазола, методы их получения, применение их в качестве агонистов фарнезоид-х-рецептора (fxr) и содержащие их фармацевтические препараты
WO2008073451A2 (en) 2006-12-11 2008-06-19 Sirtris Pharmaceuticals, Inc. Benzoimidazole derivatives as sirtuin (sir) modulating compounds
CN101983384A (zh) 2007-11-30 2011-03-02 葛兰素史密斯克莱有限责任公司 脯氨酰羟化酶抑制剂
US8685970B2 (en) 2008-05-01 2014-04-01 GlaxoSmithKline, LLC Quinolines and related analogs as sirtuin modulators
AU2009248774B2 (en) 2008-05-23 2012-05-31 Novartis Ag Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors
JP5631310B2 (ja) 2008-07-23 2014-11-26 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 三環式ピラゾロピリジンキナーゼ阻害剤
US20130072473A1 (en) 2011-05-09 2013-03-21 Proteostasis Therapeutics, Inc. Compounds for treating protein folding disorders
US9394297B2 (en) 2012-02-28 2016-07-19 Amgen Inc. Amides as pim inhibitors
ES2625029T3 (es) * 2012-04-26 2017-07-18 Bristol-Myers Squibb Company Derivados del imidazotiadiazol como inhibidores del receptor 4 activado por proteasa (Par4) para el tratamiento de la agregación de plaquetas
BR112014026651A8 (pt) * 2012-04-26 2018-01-16 Bristol Myers Squibb Co derivados de imidazotiadiazol e de imidazopiridazina como inibidores do receptor ativado por proteases 4 (par4) para o tratamento de agregação plaquetária
LT3632919T (lt) 2012-04-26 2023-02-27 Bristol-Myers Squibb Company Imidazotiadiazolo ir imidazopirazino dariniai, kaip proteazės aktyvuoto receptoriaus 4 (par4) inhibitoriai, skirti trombocitų agregacijos gydymui
WO2015077550A1 (en) * 2013-11-22 2015-05-28 University Of Kentucky Research Foundation Arylquinoline and analog compounds and use thereof to treat cancer
US9617279B1 (en) 2014-06-24 2017-04-11 Bristol-Myers Squibb Company Imidazooxadiazole compounds
US9598419B1 (en) 2014-06-24 2017-03-21 Universite De Montreal Imidazotriazine and imidazodiazine compounds
US10238638B2 (en) 2015-02-26 2019-03-26 Universite De Montreal Benzothiazole and benzothiophene compounds
ES2929208T3 (es) 2015-02-26 2022-11-25 Univ Montreal Compuestos de imidazotiadiazol como inhibidores de PAR4
JP2018525371A (ja) * 2015-07-30 2018-09-06 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ アリール置換された二環式ヘテロアリール化合物
CN109689649B (zh) 2016-07-14 2022-07-19 百时美施贵宝公司 经二环杂芳基取代的化合物
EP3484874B1 (en) 2016-07-14 2020-04-29 Bristol-Myers Squibb Company Monocyclic heteroaryl substituted compounds
WO2018013774A1 (en) * 2016-07-14 2018-01-18 Bristol-Myers Squibb Company Bicyclic heteroaryl substituted compounds
CN109689664B (zh) 2016-07-14 2022-04-15 百时美施贵宝公司 作为par4抑制剂的三环杂芳基取代的喹啉和氮杂喹啉化合物

Also Published As

Publication number Publication date
WO2018013776A1 (en) 2018-01-18
US20210188877A1 (en) 2021-06-24
JP2019524732A (ja) 2019-09-05
EP3484894B1 (en) 2020-08-19
US11932658B2 (en) 2024-03-19
US12528827B2 (en) 2026-01-20
US20190315774A1 (en) 2019-10-17
JP6903732B2 (ja) 2021-07-14
KR102468661B1 (ko) 2022-11-17
US20240309019A1 (en) 2024-09-19
KR20190026906A (ko) 2019-03-13
EP3484894A1 (en) 2019-05-22
CN109689664B (zh) 2022-04-15
CN109689664A (zh) 2019-04-26

Similar Documents

Publication Publication Date Title
ES2823127T3 (es) Compuestos tricíclicos de quinolina y azaquinolina sustituidos con heteroarilo como inhibidores de PAR4
US12060347B2 (en) Bicyclic heteroaryl substituted compounds
AU2020343671B2 (en) RIP1 inhibitory compounds and methods for making and using the same
US10730868B2 (en) Bicyclic heteroaryl substituted compounds
EP4055021B1 (en) Heterocyclic rip1 inhibitory compounds
CA3257445A1 (en) Oxazepine aza-tetracycline compounds and their uses
ES2924371T3 (es) Compuestos tricíclicos y su uso como inhibidores de la fosfodiesterasa
EA025520B1 (ru) N-(ГЕТЕРО)АРИЛПИРРОЛИДИНОВЫЕ ПРОИЗВОДНЫЕ ПИРАЗОЛ-4-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ И ПИРРОЛ-3-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ
KR20160098392A (ko) Nrf2 조절제
CN109689642B (zh) 经单环杂芳基取代的化合物
CN112409378A (zh) 三环pi3k抑制剂化合物及其使用方法
US20220315597A1 (en) Tricyclic compounds and their use
CA3162281A1 (en) Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use
AU2023216951A1 (en) Compounds having a t-structure formed by at least four cycles for use in the treatment of cancer and other indications
WO2022166796A1 (zh) 嘧啶或吡啶并杂环类腺苷受体抑制剂及其制备方法和用途
NZ623098A (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.